Literature DB >> 350041

Biochemical, immunological, and cell genetic studies in glycogenosis type II.

A J Reuser, J F Koster, A Hoogeveen, H Galjaard.   

Abstract

Fibroblasts from patients with the adult, juvenile, and infantile form of glycogenosis type II (Pompe disease) were cultured under standardized conditions, and the activity of acid alpha-glucosidase (E.C.3.2.1.20) towards glycogen, maltose, and 4-methylumbelliferyl-alpha-D-glucopyranoside was measured. Glycogen levels in muscle biopsies and in cultured fibroblasts from patients were determined. Residual enzyme activities varying from 7%-22% were detected in fibroblasts from patients with the adult form but not from patients with the infantile form of glycogenosis II. An inverse correlation was found between the severity of the clinical manifestation and the degree of residual enzyme activity in the fibroblasts. The kinetic and electrophoretic properties of acid alpha-glucosidase in fibroblasts from the adult patients and from control individuals were similar. Immunological studies suggested that the decrease of acid alpha-glucosidase activity is caused by a mutation that affects the production or degradation of the enzyme rather than its catalytic activity. Complementation studies were carried out by fusing fibroblasts from patients with the adult, juvenile, and infantile form of glycogenosis II, but neither conventional assays on multikaryons nor enzyme assays on single binuclear heterokaryons gave any evidence for genetic heterogeneity among these forms.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 350041      PMCID: PMC1685555     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  19 in total

1.  Genetic complementation after fusion of Tay-Sachs and Sandhoff cells.

Authors:  G H Thomas; H A Taylor; C S Miller; J Axelman; B R Migeon
Journal:  Nature       Date:  1974-08-16       Impact factor: 49.962

2.  A method for rapid prenatal diagnosis of glycogenosis II (Pompe's disease).

Authors:  H Galjaard; M Mekes; D E Josselin de Jong JE; M F Niermeijer
Journal:  Clin Chim Acta       Date:  1973-12-27       Impact factor: 3.786

3.  Rodent and human acid -glucosidase. Purification, properties and inhibition by antibodies. Investigation in type II glycogenosis.

Authors:  T de Barsy; P Jacquemin; P Devos; H G Hers
Journal:  Eur J Biochem       Date:  1972-11-21

4.  The use of leucocytes as an aid in the diagnosis of a variant of glycogen storage disease type II (Pompe's disease).

Authors:  J F Koster; R G Slee; W C Hülsmann
Journal:  Eur J Clin Invest       Date:  1972-11       Impact factor: 4.686

5.  The spectrum and diagnosis of acid maltase deficiency.

Authors:  A G Engel; M R Gomez; M E Seybold; E H Lambert
Journal:  Neurology       Date:  1973-01       Impact factor: 9.910

6.  Subcellular distribution of acid and neutral alpha-glucosidases in normal, acid maltase deficient, and myophosphorylase deficient human skeletal muscle.

Authors:  C Angelini; A G Engel
Journal:  Arch Biochem Biophys       Date:  1973-05       Impact factor: 4.013

7.  Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies.

Authors:  A G Engel
Journal:  Brain       Date:  1970       Impact factor: 13.501

8.  Studies of lysosomal alpha-glucosidase. II. Kinetics of action of the rat liver enzyme.

Authors:  P L Jeffrey; D H Brown; B I Brown
Journal:  Biochemistry       Date:  1970-03-17       Impact factor: 3.162

9.  Some properties of human liver acid alpha-glucosidase.

Authors:  J F Koster; R G Slee
Journal:  Biochim Biophys Acta       Date:  1977-05-12

10.  Comparative study of acid maltase deficiency. Biochemical differences between infantile, childhood, and adult types.

Authors:  C Angelini; A G Engel
Journal:  Arch Neurol       Date:  1972-04
View more
  27 in total

1.  Clinical and biochemical observations in a patient with combined Pompe disease and cblC mutation.

Authors:  F A Wijburg; D S Rosenblatt; G D Vos; J W Oorthuys; L G van't Hek; B J Poorthuis; M K Sanders; R B Schutgens
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

2.  Micropatterned substrates with physiological stiffness promote cell maturation and Pompe disease phenotype in human induced pluripotent stem cell-derived skeletal myocytes.

Authors:  Nunnapas Jiwlawat; Eileen M Lynch; Brett N Napiwocki; Alana Stempien; Randolph S Ashton; Timothy J Kamp; Wendy C Crone; Masatoshi Suzuki
Journal:  Biotechnol Bioeng       Date:  2019-06-20       Impact factor: 4.530

3.  Seven cases of Pompe disease from Greece.

Authors:  M Kroos; P Manta; I Mavridou; F Muntoni; D Halley; R Van der Helm; D Zaifeiriou; A Van der Ploeg; A Reuser; H Michelakakis
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

4.  Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.

Authors:  Wei Zheng; Janak Padia; Daniel J Urban; Ajit Jadhav; Ozlem Goker-Alpan; Anton Simeonov; Ehud Goldin; Douglas Auld; Mary E LaMarca; James Inglese; Christopher P Austin; Ellen Sidransky
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

5.  Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.

Authors:  A J McVie-Wylie; K L Lee; H Qiu; X Jin; H Do; R Gotschall; B L Thurberg; C Rogers; N Raben; M O'Callaghan; W Canfield; L Andrews; J M McPherson; R J Mattaliano
Journal:  Mol Genet Metab       Date:  2008-06-05       Impact factor: 4.797

6.  Pompe's disease in Chinese and prenatal diagnosis by determination of alpha-glucosidase activity.

Authors:  C Y Lin; B Hwang; K J Hsiao; Y R Jin
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

7.  Characterization of the molecular defect in infantile and adult acid alpha-glucosidase deficiency fibroblasts.

Authors:  N G Beratis; G U LaBadie; K Hirschhorn
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

8.  Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.

Authors:  T Kikuchi; H W Yang; M Pennybacker; N Ichihara; M Mizutani; J L Van Hove; Y T Chen
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

9.  Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Kunil K Raval; Ran Tao; Brent E White; Willem J De Lange; Chad H Koonce; Junying Yu; Priya S Kishnani; James A Thomson; Deane F Mosher; John C Ralphe; Timothy J Kamp
Journal:  J Biol Chem       Date:  2014-12-08       Impact factor: 5.157

10.  Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice.

Authors:  Nina Raben; Kanneboyina Nagaraju; Alicia Lee; Nina Lu; Yesenia Rivera; Tejas Jatkar; John J Hopwood; Paul H Plotz
Journal:  Transgenic Res       Date:  2003-04       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.